BRENTWOOD, Tenn. / Nov 05, 2024 / Business Wire / Ardent Health (NYSE: ARDT), a leading provider of healthcare in growing midsize urban communities across the U.S., today announced that members of the Company’s management team will participate in the following upcoming investor conferences:
A live audio webcast of the fireside chat discussions will be available at the Investor Relations section of the Company’s website, at https://ir.ardenthealth.com, and a replay will be available for 90 days using the same link.
In conjunction with these conferences, the Ardent Health management team will be available to participate in one-on-one meetings with investors registered to attend each conference. For more information, please contact your sales representative at the host firm, or Dave Styblo, Ardent Health’s senior vice president of investor relations at This email address is being protected from spambots. You need JavaScript enabled to view it..
About Ardent Health
Ardent Health (NYSE: ARDT) is a leading provider of healthcare in growing mid-sized urban communities across the U.S. With a focus on people and investments in innovative services and technologies, Ardent is passionate about making healthcare better and easier to access. Through its subsidiaries, the Company delivers care through a system of 30 acute care hospitals and more than 200 sites of care with over 1,700 affiliated providers across six states. For more information, please visit www.ardenthealth.com.
Last Trade: | US$13.77 |
Daily Change: | 0.46 3.46 |
Daily Volume: | 570,598 |
Market Cap: | US$1.970B |
May 06, 2025 March 31, 2025 February 26, 2025 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load